Project Grant DP2AG086138
Award Date
9/15/23
Completion Date
8/31/26
Dollars Obligated
$1.6M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,858,368.00 to Brigham & Women's Hospital Inc. to support research on the role of the SORL1-retromer biology in the pathogenesis of Alzheimer's disease. The award has an initial term from September 30, 2024 to August 31, 2027. Brigham & Women's Hospital Inc. is a prominent academic medical center and research institution in Boston, Massachusetts, affiliated with Harvard Medical...
The National Institutes of Health's National Institute on Aging awarded a $5,063,226 Project Grant to Brigham and Women's Hospital Inc. under the Aging Research program (CFDA 93.866) for the period of September 1, 2022 through August 31, 2025. The grant funds research to analyze the functional role of glial cells in tauopathy and Alzheimer's disease. Researchers will use genetic approaches in Drosophila to identify glial proteins and pathways that influence tau neurotoxicity in aging adult fly...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), provides $487,574 in funding to investigate the role of reactive astrocytes in the propagation and clearance of tau protein in Alzheimer's disease. The key objectives are to: Determine if astrocyte GFAP (glial fibrillary acidic protein) upregulation can attenuate the trans-synaptic neuron-to-neuron propagation of...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $784,596 to Northeastern University to conduct comprehensive and cell type-specific proteogenomic profiling of aberrant and mis-processed proteins in Alzheimer's disease (AD) and tauopathy models. The project aims to substantially expand understanding of protein dysfunctions in AD by applying state-of-the-art proteomic methods paired with proteogenomics across multiple brain regions, AD stages,...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,173,794 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on enhancing brain resilience to Alzheimer's disease by targeting adult hippocampal neurogenesis. The project aims to explore the mechanisms by which adult hippocampal neurogenesis cooperates with brain-derived neurotrophic factor (BDNF) to potentially slow cognitive decline in...
This Project Grant award of $1,526,066 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to investigate the mechanisms by which the protein tau and mitochondrial dysfunction contribute to a broad spectrum of neurodegenerative diseases, including Alzheimer's disease (AD) and related dementias (AD/ADRD). The goal is to use in vivo animal models and human cell culture models to examine how tau regulation of mitochondrial reverse electron transfer (RET) is...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $757,027 to the University of Washington to conduct research on the synergistic relationship between tau and TDP-43 proteins in Alzheimer's disease. The research aims to identify mechanisms that drive the interaction between these two pathological hallmarks of Alzheimer's and how they contribute to cognitive decline and neurodegeneration. Key activities include using C. elegans models to...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will investigate the role of glial fibrillary acidic protein (GFAP) upregulation in reactive astrocytes and its impact on tripartite excitatory synapses in a tauopathy mouse model of Alzheimer's disease. Specifically, the $452,550 award to The General Hospital Corporation (dba Massachusetts General Hospital) will overexpress GFAP in astrocytes and blunt GFAP upregulation to evaluate changes in the...
The National Institute on Aging (NIA), under its Aging Research Federal Grant Program (CFDA 93.866), awarded a $154,748 Project Grant to Brigham & Women's Hospital Inc. to develop an ultrasensitive blood-based diagnostic tool for accurately detecting and monitoring Alzheimer's disease (AD). The project aims to engineer a diagnostic pipeline that leverages extracellular vesicles (EVs) and single molecule detection technology to quantify low-abundance AD protein biomarkers, particularly...
The University of Massachusetts Medical School (UMass Medical) was awarded a $1,507,500 Project Grant from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to conduct a study on spatial single-cell analysis of somatic mutations in the human brain during aging and neurodegeneration. The goal is to develop and apply new single-cell whole-genome sequencing methods to study somatic mutations in neurons from late-stage Alzheimer's disease and...